Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 1.39
(9.92%)
SEK 1.39
(9.92%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 9.06 Million SEK | -6.25% |
| 2022 | 9.67 Million SEK | 23.27% |
| 2021 | 7.84 Million SEK | 20.28% |
| 2020 | 6.52 Million SEK | -6.29% |
| 2019 | 6.96 Million SEK | 16.15% |
| 2018 | 5.99 Million SEK | 58.78% |
| 2017 | 3.77 Million SEK | 1.13% |
| 2016 | 3.73 Million SEK | 40.87% |
| 2015 | 2.65 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 FY | 9.06 Million SEK | -6.25% |
| 2023 Q1 | 11.78 Million SEK | 21.79% |
| 2023 Q2 | 11.78 Million SEK | 0.0% |
| 2023 Q4 | 9.06 Million SEK | 0.0% |
| 2023 Q3 | 9.06 Million SEK | -23.03% |
| 2022 Q3 | 9.67 Million SEK | -6.13% |
| 2022 Q1 | 10.3 Million SEK | 31.31% |
| 2022 Q2 | 10.3 Million SEK | 0.0% |
| 2022 FY | 9.67 Million SEK | 23.27% |
| 2022 Q4 | 9.67 Million SEK | 0.01% |
| 2021 FY | 7.84 Million SEK | 20.28% |
| 2021 Q1 | 6.78 Million SEK | 4.03% |
| 2021 Q4 | 7.84 Million SEK | 0.0% |
| 2021 Q3 | 7.84 Million SEK | 15.62% |
| 2021 Q2 | 6.78 Million SEK | 0.0% |
| 2020 Q4 | 6.52 Million SEK | 0.0% |
| 2020 Q2 | 8.55 Million SEK | 24.69% |
| 2020 Q3 | 6.52 Million SEK | -23.74% |
| 2020 Q1 | 6.86 Million SEK | -1.45% |
| 2020 FY | 6.52 Million SEK | -6.29% |
| 2019 Q4 | 6.96 Million SEK | 16.03% |
| 2019 Q2 | 5.9 Million SEK | 17.95% |
| 2019 FY | 6.96 Million SEK | 16.15% |
| 2019 Q1 | 5 Million SEK | -16.52% |
| 2019 Q3 | 6 Million SEK | 1.66% |
| 2018 Q4 | 5.99 Million SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 FY | 5.99 Million SEK | 58.78% |
| 2018 Q2 | 4.91 Million SEK | 0.0% |
| 2017 Q4 | 3.77 Million SEK | -23.66% |
| 2017 FY | 3.77 Million SEK | 1.13% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | 4.94 Million SEK | 0.0% |
| 2016 FY | 3.73 Million SEK | 40.87% |
| 2016 Q4 | 3.73 Million SEK | 0.0% |
| 2015 FY | 2.65 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alzinova AB (publ) | -3.27 Million SEK | 376.632% |
| Amniotics AB (publ) | 534 Thousand SEK | -1598.127% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 55.61% |
| Genovis AB (publ.) | 14.9 Million SEK | 39.161% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 74.26% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 1150.754% |
| Saniona AB (publ) | 1.00 SEK | -906799900.0% |
| Simris Alg AB (publ) | 1.09 Million SEK | -731.164% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | 2.08 Million SEK | -335.962% |
| Active Biotech AB (publ) | -2500.00 SEK | 362820.0% |
| Camurus AB (publ) | 100.95 Million SEK | 91.018% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -124.789% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 610328.802% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 465125.641% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 657.688% |
| NextCell Pharma AB | 545.23 Thousand SEK | -1563.13% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 91.514% |
| Xintela AB (publ) | 398 Thousand SEK | -2178.392% |
| Ziccum AB (publ) | -4.18 Million SEK | 316.472% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 2128.699% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 79.288% |
| CombiGene AB (publ) | -1.79 Million SEK | 604.058% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 62.295% |
| Intervacc AB (publ) | 10.48 Million SEK | 13.498% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -453399900.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 227.074% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 335.105% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -906700.0% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -187.873% |
| Biovica International AB (publ) | 2.19 Million SEK | -312.369% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -906799900.0% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -1195.429% |
| 2cureX AB (publ) | -1000.00 SEK | 906900.0% |
| I-Tech AB | 4.28 Million SEK | -111.869% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 7.394% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 283.972% |
| Nanologica AB (publ) | 2.97 Million SEK | -205.012% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 23.438% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 2923.647% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -273.938% |
| Pila Pharma AB (publ) | 1.00 SEK | -906799900.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -782.101% |